Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Executive Summary
Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.
You may also be interested in...
Medtronic: Doing Just What the Doctors Order
Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
Medtronic: Doing Just What the Doctors Order
Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
Profiles of COURAGE: Another Speed Bump for Stents or Flawed Trial?
Cardiologists and interventionalists continue to disagree on the importance of the COURAGE trial results. Academic disputes aside, the question for industry is whether this study will further drive down stent usage.